Time filter

Source Type

Pereira Vazquez M.,Complexo Universitario Hospitalario Of Ourense | Fernandez Montes A.,Complexo Universitario Hospitalario Of Ourense | Castro Gomez J.E.,Complexo Universitario Hospitalario Of Ourense | Firvida Perez J.L.,Complexo Universitario Hospitalario Of Ourense | And 2 more authors.
Atencion Farmaceutica | Year: 2012

Objectives: To assess the efficacy, toxicity and therapeutic adherence of gefitinib in the treatment of non-microcytic lung cancer. Also, to confirm the clinical profile of patients with mutations in the EGFR (Epidermal Growth Factor Receptor) in our environment. And, to assess the effectiveness of integrating the Pharmacy Units into the Oncology Services. Method: We retrospectively reviewed those cases with mutated EGFR treated for first-line non-microcytic lung cancer with gefitinib at our center in 2011, by evaluating the progression-free survival rate, toxicity and therapeutic adherence. Results: Twelve patients were evaluated finding an 83% response rate, a progression-free survival of 10.3 months and a low incidence of adverse effects without any need for dose reduction, as well as a therapeutic adherence of 100%. Mutation was related to a clinical profile corresponding to women, with a histology of adenocarcinoma and non-smokers. Conclusions: Gefitinib is effective in first-line lung cancer with a low incidence of adverse effects and a high therapeutic adherence in our environment as a result of a multidisciplinary work between oncologists and pharmacists.

Loading Complexo Universitario Hospitalario Of Ourense collaborators
Loading Complexo Universitario Hospitalario Of Ourense collaborators